Nisha Kotecha
Critical Care Medicine · Summit, NJNPI 1073873956
Payments from drug & device makers
Across 113 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$585
- GSK$392
- Boehringer Ingelheim$173
- Regeneron Healthcare Solutions, Inc.$144
- Amgen$143
- Mylan Specialty L.p.$91
- plus $422 from 13 others
What the payments were for
- Food & beverage$1,89497%
- Education$563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $585 |
| GSK | 22 | $392 |
| Boehringer Ingelheim | 11 | $173 |
| Regeneron Healthcare Solutions, Inc. | 10 | $144 |
| Amgen | 8 | $143 |
| Mylan Specialty L.p. | 6 | $91 |
| Merck | 4 | $67 |
| Incyte Corporation | 3 | $51 |
| Genentech USA, Inc. | 3 | $49 |
| Sanofi | 3 | $45 |
| Viatris Specialty LLC | 2 | $34 |
| Kaleo, Inc. | 2 | $32 |
| Insmed, Inc. | 2 | $32 |
| Octapharma USA, Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Resmed Corp | 1 | $18 |
| United Therapeutics Corporation | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$125
How this compares
$1,950 in reported general payments places this provider in the 70th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 55 | $721,506 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 350 | $284,924 |
| Breo ElliptaFluticasone/Vilanterol | 124 | $68,974 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $64,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $50,448 |
| Incruse ElliptaUmeclidinium Bromide | 61 | $27,309 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $13,551 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $12,824 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $11,705 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,659 |
| Arnuity ElliptaFluticasone Furoate | 26 | $9,491 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $7,657 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $6,630 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 62 | $6,529 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $5,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $173 | $759,540122 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $392 | $455,071677 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $585 | $68,782128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Summit
- Fariborz RezaiLivingston$2.4M
- Ronak ShahHackensack$439K
- Eric SztejmanMarlton$231K
- Eric TellerHackensack$217K
- Steven ChangNewark$191K
- Jonathan GalliMarlton$128K
- Keith RoseHackensack$112K
- R Phillip DellingerCamden$74K
- Theodore PlushCamden$63K
- Ricardo VerdinerNew Brunswick$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.